With 2019 behind us, it’s time for everyone to start anew and welcome 2020 into their lives. It’s hard to be fond of 2019 considering the impact my chronic illness had on my life. I spent practically a third of the year on bed rest because of severe…

I received an email from a friend I hadn’t heard from in some time. She told me that her nephew and his wife just had a baby and he has been diagnosed with hemophilia. She had ordered my book to send to her niece and was hoping I would…

Recently, I was browsing the website of the National Hemophilia Foundation and came across a series of videos encouraging people with hemophilia to have regular testing for inhibitors. As I watched the videos, it occurred to me that women with hemophilia don’t talk much about inhibitors.

I’d been sick with acute respiratory troubles for almost a week. Not a minute had gone by without a sniffle or a sneeze. My sinuses had been painful and horribly congested, my throat inflamed, and my stomach upset due to the collection of phlegm in my digestive tract. (Don’t get…

My family entered the hemophilia community more than 23 years ago with the birth of my oldest son. During our time with the bleeding disorders community, my wife and I learned to access ports, treat and perform peripheral sticks, and negotiate difficult circumstances. We did not receive a manual titled…

I have begun the year on a high note: I can park both cars in my garage. My family pitched in to help with a clear out. We tossed things we no longer need and donated useful items. It was a fantastic feeling to get rid of the things that…

As early as September, colorful Christmas lights adorn all sorts of spaces in the Philippines. Families begin decorating their homes and stores start to roll out out holiday promotions: holiday-themed drinks, planners for collecting stickers — you name it. At the onset of such traditions, one can feel the so-called…

Sangamo Therapeutics has handed over the development of SB-525, a gene therapy for hemophilia A, to Pfizer, which will now advance the therapy into Phase 3 clinical trials. Pfizer has already started recruiting participants for the lead-in Phase 3 trial (NCT03587116). which will support…

This month has brought a holiday rush of hemophilia news on potential new treatments, studies, and acquisitions — all of which serve to raise hope during this solstice season, as we move past the shortest day of the year. Solstice can be a…

Takeda has presented new real-world data to support the cost-effectiveness and persistent benefits to patients of its hemophilia A and B therapies: Adynovate [antihemophilic factor (recombinant), PEGylated] and Feiba (anti-inhibitor coagulant complex). The findings were discussed at the recent 61st American Society of Hematology…